FDA
-
-
-
-
-
-
-
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
-
-
-
-
-
-
-
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
-
-
-
-
-
-
-
ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
-
-
-
-
-
-
-
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
-
-
-
-
-
-
-
Abbott receives CE Mark for dual-energy heart rhythm catheter in Europe
-
-
-
-
-
-
-
Abbott Reports Second-Quarter 2025 Results
-
-
-
-
-
-
-
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
-
334,836 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


